{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"}],"units":"Participants"}],"description":"TFR is defined as no confirmed loss of MR4 (Molecular response 4.0 log reduction from baseline) or loss of MMR (major molecular response) and no re-starting of nilotinib therapy within 12 months following cessation of nilotinib. Confirmed loss of MR4 is two consecutive BCR-ABL \\> 0.01% IS. Loss of MMR does not require confirmation.","groups":[{"description":"TFR is defined as no confirmed loss of MR4 (Molecular response 4.0 log reduction from baseline) or loss of MMR (major molecular response) and no re-starting of nilotinib therapy within 12 months following cessation of nilotinib. Confirmed loss of MR4 is two consecutive BCR-ABL \\> 0.01% IS. Loss of MMR does not require confirmation.","id":"OG000","title":"TFR Phase"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full analysis set (FAS) included all patients who completed the consolidation phase successfully and entered the TFR phase.","reportingStatus":"POSTED","timeFrame":"first 48 weeks following nilotinib cessation","title":"Percentage of Participants in TFR Within 48-weeks Following Nilotinib Cessation","type":"PRIMARY","unitOfMeasure":"Participants"}